Expert Insights

Videos

Novel Therapies for Non–Transfusion-Dependent and Transfusion-Dependent Thalassemia

11/03/2022

Sujit Sheth, MD, explains the pathophysiology of thalassemia and outlines novel therapies addressing unmet needs in this treatment landscape, including therapies with curative intent and those without curative intent.

Sujit Sheth, MD, explains the...

11/03/2022

Oncology

Andrea Necchi, MD, San Raffaele Hospital

Videos

3-Year Efficacy of Neoadjuvant Pembrolizumab Before Radical Cystectomy For Muscle-Invasive Bladder Cancer

11/03/2022

Andrea Necchi, MD, shares follow-up data from the phase 2 PURE-01 trial, confirming the sustained efficacy of neoadjuvant pembrolizumab before radical cystectomy in patients with muscle-invasive urothelial bladder cancer.

Andrea Necchi, MD, shares...

11/03/2022

Oncology

Videos

Managing Peripheral Neuropathies Associated With Waldenström Macroglobulinemia

11/02/2022

Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.

Norman Latov, MD, outlines the...

11/02/2022

Oncology

Videos

Subcutaneous Epcoritamab With Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma

11/02/2022

Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.

Lorenzo Falchi, MD, presents...

11/02/2022

Oncology

Videos

Do All Patients Diagnosed With Waldenström Macroglobulinemia Require Immediate Intervention?

11/02/2022

Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.

Morie Gertz, MD, discusses...

11/02/2022

Oncology

Lipika Goyal, MD, Stanford Cancer Center

Videos

Futibatinib Receives FDA Approval for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions and Rearrangements

10/31/2022

Lipika Goyal, MD, shares her insight about the recent FDA approval of futibatinib for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements and discusses findings from the FOENIX-CCA2 trial, which led to the approval.

Lipika Goyal, MD, shares her...

10/31/2022

Oncology

Kevin Kalinsky, MD, MS, Director, Glenn Family Breast Center, Winship Cancer Institute at Emory University

Videos

Right Sizing HR-Positive Breast Cancer Adjuvant Therapy With Genomic Risk Stratifying Assays

10/28/2022

Kevin Kalinsky, MD, MS, shares his insights on right sizing adjuvant therapy for HR-positive breast cancer with the use of genomic risk stratifying assays.

Kevin Kalinsky, MD, MS, shares...

10/28/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology